Identification of putative gene-based markers of renal toxicity

被引:187
作者
Amin, RA
Vickers, AE
Sistare, F
Thompson, KL
Roman, RJ
Lawton, M
Kramer, J
Hamadeh, HK
Collins, J
Grissom, S
Bennett, L
Tucker, CJ
Wild, S
Kind, C
Oreffo, V
Davis, JW
Curtiss, S
Naciff, JM
Cunningham, M
Tennant, R
Stevens, J
Car, B
Bertram, TA
Afsharil, CA
机构
[1] NIEHS, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] US FDA, Ctr Drug Evaluat & Res, Laurel, MD USA
[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[5] Physiogenix Inc, Milwaukee, WI USA
[6] Pfizer Inc, St Louis, MO USA
[7] Pfizer Inc, Groton, CT 06340 USA
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
[9] Schering Plough Res Inst, Lafayette, NJ USA
[10] Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH USA
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Bristol Myers Squibb Co, Wilmington, DE USA
关键词
biomarkers; cisplatin; gentamicin; microarrays; nephrotoxicity; proximal tubule; puromycin; toxicogenomics;
D O I
10.1289/ehp.6683
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
This study, designed and conducted as part of the International Life Sciences Institute working group on the Application of Genomics and Proteomics, examined the changes in the expression profile of genes associated with the administration of three different nephrotoxicants-cisplatin, gentamicin, and puromycin-to assess the usefulness of microarrays in the understanding of mechanism(s) of nephrotoxicity. Male Sprague-Dawley rats were treated with daily doses of puromycin (5-20 mg/kg/day for 21 days), gentamicin (2-240 mg/kg/day for 7 days), or a single dose of cisplatin (0.1-5 mg/kg). Groups of rats were sacrificed at various times after administration of these compounds for standard clinical chemistry, urine analysis, and histological evaluation of the kidney. RNA was extracted from the kidney for microarray analysis. Principal component analysis and gene expression-based clustering of compound effects confirmed sample separation based on dose, time, and degree of renal toxicity. In addition, analysis of the profile components revealed some novel changes in the expression of genes that appeared to be associated with injury in specific portions of the nephron and reflected the mechanism of action of these various nephrotoxicants. For example, although puromycin is thought to specifically promote injury of the podocytes in the glomerulus, the changes in gene expression after chronic exposure of this compound suggested a pattern similar to the known proximal tubular nephrotoxicants cisplatin and gentamicin; this prediction was confirmed histologically. We conclude that renal gene expression profiling coupled with analysis of classical end points affords promising opportunities to reveal potential new mechanistic markers of renal toxicity.
引用
收藏
页码:465 / 479
页数:15
相关论文
共 80 条
[1]  
*AFF INC, 2003, TECHN DOC MAN
[2]   Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity [J].
Andoh, TF ;
Gardner, MP ;
Bennett, WM .
TRANSPLANTATION, 1997, 64 (09) :1236-1240
[3]  
*APPL BIOS, 1997, US B, V2
[4]  
AULITZKY WK, 1992, P SOC EXP BIOL MED, V199, P93
[5]   Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration [J].
Bailly, V ;
Zhang, ZW ;
Meier, W ;
Cate, R ;
Sanicola, M ;
Bonventre, JV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (42) :39739-39748
[6]   Computational selection of distinct class- and subclass-specific gene expression signatures [J].
Bushel, PR ;
Hamadeh, HK ;
Bennett, L ;
Green, J ;
Ableson, A ;
Misener, S ;
Afshari, CA ;
Paules, RS .
JOURNAL OF BIOMEDICAL INFORMATICS, 2002, 35 (03) :160-170
[7]   MAPS: a microarray project system for gene expression experiment information and data validation [J].
Bushel, PR ;
Hamadeh, H ;
Bennett, L ;
Sieber, S ;
Martin, K ;
Nuwaysir, EF ;
Johnson, K ;
Reynolds, K ;
Paules, RS ;
Afshari, CA .
BIOINFORMATICS, 2001, 17 (06) :564-565
[8]  
Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504
[9]  
Christensson A, 2003, NEPHRON PHYSIOL, V94, P19, DOI [10.1159/000071287, DOI 10.1159/000071287]